Sequent Scientific Limited (SEQUENT) AI Stock Analysis

• Market Cap: ₹43.62B
• Dividend Yield: N/A
• Average Volume (3M): 42.15K
• Price to Earnings (P/E): 198.8
• Beta (1Y): 1.28
• Revenue Growth: 13.26%
• EPS Growth: N/A
• Country: IN
• Employees: 1,195
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 250,334,990
• 10 Day Avg. Volume: 49,590
• 30 Day Avg. Volume: 42,148
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹176.00
• Price Target Upside: 1.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: ₹176.00 ▲(1.00% Upside)

The overall stock score of 52 reflects a mixed outlook for Sequent Scientific Limited. The company's financial performance shows a strong recovery in profitability and cash flow management, which is a positive sign. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The absence of earnings call insights and corporate events leaves the analysis reliant on existing financial and market data.

Sequent Scientific Limited Business Overview & Revenue Model

Company Description

Sequent Scientific Limited (SEQUENT) is a leading integrated pharmaceutical company that operates primarily in the animal health sector. With a strong presence in over 100 countries, the company specializes in manufacturing and marketing a wide range of veterinary pharmaceutical products. Sequent's core offerings include active pharmaceutical ingredients (APIs), formulations, and analytical services, catering to both livestock and companion animals. The company is committed to innovation, high-quality standards, and sustainable practices in the animal health industry.

How the Company Makes Money

Sequent Scientific Limited generates revenue through multiple streams, primarily from the sale of veterinary pharmaceutical products. The company's revenue model is anchored in manufacturing and distributing active pharmaceutical ingredients (APIs) and formulations to both domestic and international markets. Additionally, Sequent offers analytical services which contribute to its earnings. The company benefits from strategic partnerships, extensive distribution networks, and a strong focus on research and development, which help in expanding its product portfolio and market reach. By leveraging its integrated operations and global presence, Sequent sustains a steady flow of income and enhances its market competitiveness.

Sequent Scientific Limited Financial Statement Overview

Summary

Sequent Scientific Limited has shown substantial recovery in profitability and cash flow management, with improved operational efficiency reflected in higher margins. However, modest revenue growth and stable leverage ratios indicate a need for strategic expansion and careful debt management.

Income Statement

Sequent Scientific Limited showed a strong recovery in net income from a loss of 358.69 million to a profit of 218.8 million in the latest year, demonstrating significant improvement in profitability. The gross profit margin improved to 47.7% in 2025, a notable increase from 40.5% in 2024. However, the revenue growth rate from 2024 to 2025 was modest at 13.5%, and the EBIT margin was strong at 29.5% in 2025. This indicates a return to operational profitability but highlights slower revenue expansion.

Balance Sheet

The company's debt-to-equity ratio remained stable around 0.68, reflecting moderate leverage. The return on equity (ROE) improved to 3.1% from a negative ROE in the previous year, showing a turnaround in profitability. The equity ratio was 44.0%, suggesting a balanced capital structure. However, the increase in total debt over the past years may pose potential risks if not managed carefully.

Cash Flow

The operating cash flow to net income ratio improved significantly, reflecting improved cash generation relative to profitability. Free cash flow saw a significant rise from negative in 2024 to 442.7 million in 2025, indicating better cash management. However, the free cash flow growth rate is not reliable due to prior negative figures, and consistent positive free cash flow will be essential for financial health.

Breakdown	Mar 2025	Mar 2023	Mar 2024	Mar 2022	Mar 2021
Income Statement
Total Revenue	15.51B	14.18B	13.66B	14.10B	13.52B
Gross Profit	7.40B	1.59B	5.53B	5.66B	6.15B
EBITDA	1.59B	-464.48M	549.80M	1.18B	2.06B
Net Income	218.80M	-1.21B	-358.69M	409.55M	954.42M
Balance Sheet
Total Assets	16.02B	15.29B	15.40B	14.51B	13.93B
Cash, Cash Equivalents and Short-Term Investments	691.40M	416.25M	687.85M	591.21M	597.03M
Total Debt	4.81B	4.44B	4.88B	3.65B	2.77B
Total Liabilities	8.32B	7.80B	8.27B	7.11B	6.16B
Stockholders Equity	7.04B	6.99B	6.57B	6.92B	7.28B
Cash Flow
Free Cash Flow	442.70M	-693.71M	-2.12M	-18.69M	619.24M
Operating Cash Flow	833.60M	168.08M	305.95M	305.95M	1.15B
Investing Cash Flow	-247.80M	-649.58M	-119.05M	-955.66M	96.48M
Financing Cash Flow	-607.30M	322.28M	45.46M	672.57M	-1.39B

Sequent Scientific Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 174.25
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SEQUENT, the sentiment is Negative. The current price of 174.25 is below the 20-day moving average (MA) of 178.87, below the 50-day MA of 185.18, and above the 200-day MA of 173.49, indicating a neutral trend. The MACD of -3.13 indicates Positive momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 35.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SEQUENT.

Sequent Scientific Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AARTIDRUGS	75 Outperform	₹44.68B	23.67		0.20%	-0.03%	21.29%
ADVENZYMES	68 Neutral	₹33.51B	24.47		1.75%	5.89%	-1.30%
GLENMARK	62 Neutral	₹580.50B	55.43		0.12%	9.39%	―
SEQUENT	52 Neutral	₹43.62B	198.76		―	13.26%	―
Sector *	50 Neutral	AU$2.58B	3.16	5.87%	2.68%	36.95%	13.61%
SPARC	41 Neutral	₹45.94B	―		―	-5.57%	23.03%

Sequent Scientific Limited Corporate Events

Sequent Scientific Releases Q2 2025 Financial Results

Sequent Scientific Limited has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, in two newspapers, The Financial Express and Nava Telangana. This announcement is part of the company’s compliance with regulatory requirements, providing stakeholders with insights into its financial performance for the specified period.